This study compares the behaviour of budesonide-containing microparticles made of Eudragit® RS or Eudragit® RS/Eudragit® RL 70:30 (w/w) prepared either by solvent evaporation or spray-drying technique. The loading efficiency of budesonide within microparticles was about 72% for microparticles prepared by solvent evaporation and around 78% for spray-dried microparticles. Thermal analyses were assessed to collect information about the structural stability of budesonide within the polymeric microspheres. The in vitro release was performed using simulating gastric (fasted state simulated gastric fluid) and intestinal (fasted state simulated intestinal fluid) fluids as the receiving solutions. After 3 h the drug release from Eudragit® RS/Eudragit® RL microparticles was about 6-fold higher than that obtained in the case of monopolymer microparticles. Using fasted state simulated intestinal fluid the drug was released between 4 and 30% in both types of preparations. Eudragit® RS microparticles showed a better protection of the drug from gastric acidity than those of Eudragit® RS/Eudragit® RL allowing us to propose Eudragit® RS microparticles as a hypothetical system of colon specific controlled delivery.

Eudragit® microparticles for the release of budesonide: A comparative study

CORTESI, Rita;RAVANI, Laura;MENEGATTI, Enea;ESPOSITO, Elisabetta;RONCONI, Franco
2012

Abstract

This study compares the behaviour of budesonide-containing microparticles made of Eudragit® RS or Eudragit® RS/Eudragit® RL 70:30 (w/w) prepared either by solvent evaporation or spray-drying technique. The loading efficiency of budesonide within microparticles was about 72% for microparticles prepared by solvent evaporation and around 78% for spray-dried microparticles. Thermal analyses were assessed to collect information about the structural stability of budesonide within the polymeric microspheres. The in vitro release was performed using simulating gastric (fasted state simulated gastric fluid) and intestinal (fasted state simulated intestinal fluid) fluids as the receiving solutions. After 3 h the drug release from Eudragit® RS/Eudragit® RL microparticles was about 6-fold higher than that obtained in the case of monopolymer microparticles. Using fasted state simulated intestinal fluid the drug was released between 4 and 30% in both types of preparations. Eudragit® RS microparticles showed a better protection of the drug from gastric acidity than those of Eudragit® RS/Eudragit® RL allowing us to propose Eudragit® RS microparticles as a hypothetical system of colon specific controlled delivery.
Cortesi, Rita; Ravani, Laura; Menegatti, Enea; Esposito, Elisabetta; Ronconi, Franco
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/1753899
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 11
social impact